# US 2026/0007745 A1 · ALDH Inhibitors to Promote Immune Cell Expansion

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0007745 A1
- Document ID: US20260007745A1
- Status: Published application
- Kind: A1
- Application number: 18/698,968
- Filed: 2022-10-07
- Published: 2026-01-08
- Earliest claimed: 2021-10-08
- Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education
- Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education
- Inventors: Ronald J. Buckanovich; Anda Mioara Vlad
- Web page: https://patentgrep.com/patent/US20260007745A1

## CPC

- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/4035: Isoindoles, e.g. phthalimide
- A61K 31/4725: containing further heterocyclic rings
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 35/15: Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells (presenting a specific antigen A61K39/00; therapeutic combinations of antibodies, or fragments thereof, and blood-derived cells A61K39/00)
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 39/0011: {Cancer antigens}
- A61K 40/19: Dendritic cells
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C12N 5/0636: {T lymphocytes}
- C12N 5/0639: {Dendritic cells, e.g. Langherhans cells in the epidermis}
- C12N 5/0645: {Macrophages, e.g. Kuepfer cells in the liver; Monocytes}
- C12N 5/0669: {Bone marrow stromal cells; Whole bone marrow (isolated stem cells from bone marrow C12N5/0647, C12N5/0663)}
- C12N 2500/38: Vitamins
- C12N 2500/40: Nucleotides, nucleosides or bases
- C12N 2501/15: Transforming growth factor beta (TGF-β)
- C12N 2501/22: Colony stimulating factors (G-CSF, GM-CSF)
- C12N 2501/2302: Interleukin-2 (IL-2)
- C12N 2501/2304: Interleukin-4 (IL-4)
- C12N 2501/2306: Interleukin-6 (IL-6)
- C12N 2501/2312: Interleukin-12 (IL-12)
- C12N 2501/2323: Interleukin-23 (IL-23)
- C12N 2501/24: Interferons [IFN]
- C12N 2501/71: Oxidoreductases (EC 1.)
- C12N 2501/999: Small molecules not provided for elsewhere
- C12N 2506/1353: from bone marrow mesenchymal stem cells (BM-MSC)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Using an aldehyde dehydrogenase-1A enzyme inhibitor (ALDHi) for expanding bone marrow cells and/or dendritic cells and for adjuvant therapy to an immunotherapy

## Claims

### Claim 1

A method of expanding bone marrow cells and/or dendritic cell populations, comprising culturing bone-marrow cells and/or dendritic cells in culture medium comprising an amount of an Aldehyde dehydrogenase-1A enzyme inhibitor (ALDHi) effective to increase a population of the bone-marrow cells and/or dendritic cells as compared to an increase in the population of the bone-marrow cells and/or dendritic cells grown in the same culture medium and conditions without the ALDHi in the culture medium.

### Claim 2 (depends on 1)

The method of claim 1, wherein the ALDHi has the
including pharmaceutically acceptable salts, solvates, and/or prodrugs thereof,
wherein:
R1 is H or C1-C3 alkyl (substituted or non-substituted);
R2 is H, C0-C3-alkyl-aryl or C0-C3-alkyl-heteroaryl, wherein the alkyls can be independently substituted or non-substituted, such as CH3, or selected from one of the following:
Y is a linker, and optionally an alkyl, alkenyl, heteroalkyl, or heteroalkenyl, where the hetero atom is S, N, or O that is optionally substituted;
R3 is H, C0-C8 alkyl, C0-C2-alkyl-aryl or C0-C2-alkyl-heteroaryl, wherein the alkyls are independently substituted or non-substituted; and
R4 is H, C1-C6 alkyl or cycloalkyl, optionally substituted, wherein one or more carbons may be replaced by oxygen, and wherein the alkyls are independently substituted or non-substituted, such as a structure of one of the following:

### Claim at position 3

3-8. (canceled)

### Claim 9 (depends on 1)

The method of claim 1, wherein the ALDHi is selected from one of the following, or a pharmaceutically acceptable salt thereof: 6-((3-fluorobenzyl)thio)-5-(o-tolyl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-1-methyl-5-(o-tolyl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-2-methyl-5-(o-tolyl)-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 1-ethyl-6-((3-fluorobenzyl)thio)-5-(o-tolyl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 2-ethyl-6-((3-fluorobenzyl)thio)-5-(o-tolyl)-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 1-(cyclopropylmethyl)-6-((3-fluorobenzyl)thio)-5-(o-tolyl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 2-(cyclopropylmethyl)-6-((3-fluorobenzyl)thio)-5-(o-tolyl)-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-1-(oxetan-3-yl)-5-(o-tolyl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-2-(oxetan-3-yl)-5-(o-tolyl)-2H-pyrazolol[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-1-(oxetan-3-ylmethyl)-5-(o-tolyl)-1H-pyrazolol[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-2-(oxetan-3-ylmethyl)-5-(o-tolyl)-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-2-methyl-5-phenyl-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 1-ethyl-6-((3-fluorobenzyl)thio)-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 2-ethyl-6-((3-fluorobenzyl)thio)-5-phenyl-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 1-(cyclopropylmethyl)-6-((3-fluorobenzyl)thio)-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 2-(cyclopropylmethyl)-6-((3-fluorobenzyl)thio)-5-phenyl-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-1-(oxetan-3-yl)-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-2-(oxetan-3-yl)-5-phenyl-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-1-(oxetan-3-ylmethyl)-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-2-(oxetan-3-ylmethyl)-5-phenyl-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one,
6-((3-fluorobenzyl)amino)-5-(o-tolyl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorophenethyl)amino)-1-methyl-5-(o-tolyl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)oxy)-1-methyl-5-(o-tolyl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorophenoxy)methyl)-1-methyl-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-(((3-fluorobenzyl)amino)methyl)-1-methyl-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-1-methyl-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-5-(2-methoxyphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-5-(3-methoxyphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-5-(4-methoxyphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one 6-((3-fluorobenzyl)thio)-1-methyl-5-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-1-methyl-5-(pyridin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-5-(2-hydroxyphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-1-methyl-5-(pyridin-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-1-methyl-5-phenethyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 5-benzyl-6-((3-fluorobenzyl)thio)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-1,5-dimethyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-(isopentylthio)-1-methyl-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-3-methyl-5-(o-tolyl)-2H-pyrazolol[3,4-d]pyrimidin-4(5H)-one, 6-(benzo[b]thiophen-2-ylmethoxy)-1-methyl-5-(o-tolyl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 5-(2-chlorophenyl)-6-(3-fluorobenzylthio)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 5-(2-chlorophenyl)-6-((3-fluorobenzyl)thio)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 5-(3-chlorophenyl)-6-((3-fluorobenzyl)thio)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 5-(4-chlorophenyl)-6-((3-fluorobenzyl)thio)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-5-(2-fluorophenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 5-cyclohexyl-6-((3-fluorobenzyl)thio)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 5-cyclopentyl-6-((3-fluorobenzyl)thio)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 5-cyclobutyl-6-((3-fluorobenzyl)thio)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, (E)-6-(3-fluorostyryl)-1-methyl-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-(3-fluorophenethyl)-1-methyl-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-(((3-fluorophenyl)amino)methyl)-1-methyl-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-(((3-fluorobenzyl)oxy)methyl)-1-methyl-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-(((3-fluorophenyl)thio)methyl)-1-methyl-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 1-methyl-6-((2-oxo-2-phenylethyl)thio)-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 3-(((1-methyl-4-oxo-5-phenyl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)thio)methyl)benzonitrile, 6-((3-methoxybenzyl)thio)-1-methyl-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-(benzylthio)-1-methyl-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 1-methyl-5-phenyl-6-((3-(2,2,2-trifluoroacetyl)benzyl)thio)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 3-(((1-methyl-4-oxo-5-phenyl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)thio)methyl)benzaldehyde, 4-(((1-methyl-4-oxo-5-phenyl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)thio)methyl)benzaldehyde, 6-((3-fluorobenzyl)oxy)-1-methyl-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 1-methyl-5-phenyl-6-((1-phenylethyl)thio)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-(((3-fluorophenyl)(methyl)amino)methyl)-1-methyl-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)oxy)-2-(oxetan-3-ylmethyl)-5-phenyl-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 2-(oxetan-3-ylmethyl)-5-phenyl-6-((1-phenylethyl)thio)-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, (R)-1-methyl-5-phenyl-6-((1-phenylethyl)thio)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, (S)-1-methyl-5-phenyl-6-((1-phenylethyl)thio)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 1-methyl-5-phenyl-6-(1-phenylethoxy)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-2-((3-methyloxetan-3-yl)methyl)-5-phenyl-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 3-((6-((3-fluorobenzyl)thio)-4-oxo-5-phenyl-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl)azetidin-1-ium sulfate, 1-methyl-5-phenyl-6-((1-phenylpropyl)thio)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((1-(3-fluorophenyl)ethyl)thio)-1-methyl-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-(cyclohexylthio)-1-methyl-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 1-(oxetan-3-yl)-5-phenyl-6-((1-phenylethyl)thio)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 2-(oxetan-3-yl)-5-phenyl-6-((1-phenylethyl)thio)-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 1-methyl-6-((2-oxocyclopentyl)thio)-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 1-methyl-6-((2-oxocyclohexyl)thio)-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 1-methyl-5-phenyl-6-((2-phenylpropan-2-yl)thio)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((1-(3-hydroxyphenyl)ethyl)thio)-1-methyl-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 1-methyl-5-phenyl-6-((1-(pyridin-2-yl)ethyl)thio)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, and 1-methyl-5-phenyl-6-((1-(pyridin-3-yl)ethyl)thio)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The method of claim 1, wherein the ALDHi is selected from 673A, 257913 (913), 258085 (085), 262548 (548), 263052 (052), 263117 (117), 263118 (118), 263119 (119), 259122 (122), 263646 (646), 264202 (202), or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 1)

The method of claim 1, wherein the ALDHi is 673A, or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 1)

The method of claim 1, wherein the ALDHi has the structure:
wherein R1 and R2 are independently or together, H, an alkyl, a cycloalkyl, together form a cycloalkyl or heterocyclic alkyl or aryl, an aryl, an alkenyl, a cycloalkyl, alkynl, or a substituted version of the aforementioned groups and R3-R6 are independently a halogen, H, an alkyl, a cycloalkyl, an aryl, an alkenyl, a cycloalkyl, alkynl, or a substituted version of the aforementioned groups, or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 13)

The method of claim 13, wherein the ALDHi has the structure:
wherein and R3-R6 are independently a halogen, H, an alkyl, a cycloalkyl, an aryl, an alkenyl, a cycloalkyl, alkynl, or a substituted version of the aforementioned groups, or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 1)

The method of claim 1, wherein the ALDHi has a structure selected from:
or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 1)

The method of claim 1, wherein the ALDHi has a structure
or a pharmaceutically acceptable salt thereof.

### Claim 17

An immunotherapy method for increasing an immune response to a pathogen or cancer cell antigen in a patient, comprising:
administering to a patient an immunotherapeutic agent for increasing an antigen-specific immune response in a patient; and
administering to the patient an adjuvant therapy to the administration of the immune cell, an amount of an aldehyde dehydrogenase-1A enzyme inhibitor (ALDHi) effective to reduce TREG activity in the patient.

### Claim 18 (depends on 17)

The method of claim 17, wherein the immunotherapeutic agent is an immune cell adapted to elicit an immune response to an antigen: an antigen-primed antigen-presenting (APC), such as a dendritic cell primed with an antigen a CAR-T cell; or a checkpoint inhibitor such as a PD1- or PDL1-targeting antibody (e.g., pembrolizumab, nivolumab, atezolizumab, or durvalumab).

### Claim at position 14

19-23. (canceled)

### Claim 24 (depends on 17)

The method of claim 17, wherein the ALDHi has the structure:
including pharmaceutically acceptable salts, solvates, and/or prodrugs thereof, wherein:
R1 is H or C1-C3 alkyl (substituted or non-substituted)
R2 is H, C0-C3-alkyl-aryl or C0-C3-alkyl-heteroaryl, wherein the alkyls can be independently substituted or non-substituted, such as CH3, or selected from one of the following:
Y is a linker, and optionally an alkyl, alkenyl, heteroalkyl, or heteroalkenyl, where the hetero atom is S, N, or O that is optionally substituted;
R3 is H, C0-C8 alkyl, C0-C2-alkyl-aryl or C0-C2-alkyl-heteroaryl, wherein the alkyls are independently substituted or non-substituted; and
R4 is H, C1-C6 alkyl or cycloalkyl, optionally substituted, wherein one or more carbons may be replaced by oxygen, and wherein the alkyls are independently substituted or non-substituted, such as a structure of one of the following:

### Claim at position 16

25-30. (canceled)

### Claim 31 (depends on 17)

The method of claim 17, wherein the ALDHi is selected from one of the following, or a pharmaceutically acceptable salt thereof: 6-((3-fluorobenzyl)thio)-5-(o-tolyl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-1-methyl-5-(o-tolyl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-2-methyl-5-(o-tolyl)-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 1-ethyl-6-((3-fluorobenzyl)thio)-5-(o-tolyl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 2-ethyl-6-((3-fluorobenzyl)thio)-5-(o-tolyl)-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 1-(cyclopropylmethyl)-6-((3-fluorobenzyl)thio)-5-(o-tolyl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 2-(cyclopropylmethyl)-6-((3-fluorobenzyl)thio)-5-(o-tolyl)-2H-pyrazolol[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-1-(oxetan-3-yl)-5-(o-tolyl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-2-(oxetan-3-yl)-5-(o-tolyl)-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-1-(oxetan-3-ylmethyl)-5-(o-tolyl)-1H-pyrazolol[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-2-(oxetan-3-ylmethyl)-5-(o-tolyl)-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-2-methyl-5-phenyl-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 1-ethyl-6-((3-fluorobenzyl)thio)-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 2-ethyl-6-((3-fluorobenzyl)thio)-5-phenyl-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 1-(cyclopropylmethyl)-6-((3-fluorobenzyl)thio)-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 2-(cyclopropylmethyl)-6-((3-fluorobenzyl)thio)-5-phenyl-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-1-(oxetan-3-yl)-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-2-(oxetan-3-yl)-5-phenyl-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-1-(oxetan-3-ylmethyl)-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-2-(oxetan-3-ylmethyl)-5-phenyl-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)amino)-5-(o-tolyl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorophenethyl)amino)-1-methyl-5-(o-tolyl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)oxy)-1-methyl-5-(o-tolyl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorophenoxy)methyl)-1-methyl-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-(((3-fluorobenzyl)amino)methyl)-1-methyl-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-1-methyl-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-5-(2-methoxyphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-5-(3-methoxyphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-5-(4-methoxyphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one 6-((3-fluorobenzyl)thio)-1-methyl-5-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-1-methyl-5-(pyridin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-5-(2-hydroxyphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-1-methyl-5-(pyridin-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-1-methyl-5-phenethyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 5-benzyl-6-((3-fluorobenzyl)thio)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-1,5-dimethyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-(isopentylthio)-1-methyl-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-3-methyl-5-(o-tolyl)-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-(benzo[b]thiophen-2-ylmethoxy)-1-methyl-5-(o-tolyl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 5-(2-chlorophenyl)-6-(3-fluorobenzylthio)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 5-(2-chlorophenyl)-6-((3-fluorobenzyl)thio)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 5-(3-chlorophenyl)-6-((3-fluorobenzyl)thio)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 5-(4-chlorophenyl)-6-((3-fluorobenzyl)thio)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-5-(2-fluorophenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 5-cyclohexyl-6-((3-fluorobenzyl)thio)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 5-cyclopentyl-6-((3-fluorobenzyl)thio)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 5-cyclobutyl-6-((3-fluorobenzyl)thio)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, (E)-6-(3-fluorostyryl)-1-methyl-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-(3-fluorophenethyl)-1-methyl-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-(((3-fluorophenyl)amino)methyl)-1-methyl-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-(((3-fluorobenzyl)oxy)methyl)-1-methyl-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-(((3-fluorophenyl)thio)methyl)-1-methyl-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 1-methyl-6-((2-oxo-2-phenylethyl)thio)-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 3-(((1-methyl-4-oxo-5-phenyl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)thio)methyl)benzonitrile, 6-((3-methoxybenzyl)thio)-1-methyl-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-(benzylthio)-1-methyl-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 1-methyl-5-phenyl-6-((3-(2,2,2-trifluoroacetyl)benzyl)thio)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 3-(((1-methyl-4-oxo-5-phenyl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)thio)methyl)benzaldehyde, 4-(((1-methyl-4-oxo-5-phenyl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)thio)methyl)benzaldehyde, 6-((3-fluorobenzyl)oxy)-1-methyl-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 1-methyl-5-phenyl-6-((1-phenylethyl)thio)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-(((3-fluorophenyl)(methyl)amino)methyl)-1-methyl-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)oxy)-2-(oxetan-3-ylmethyl)-5-phenyl-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 2-(oxetan-3-ylmethyl)-5-phenyl-6-((1-phenylethyl)thio)-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, (R)-1-methyl-5-phenyl-6-((1-phenylethyl)thio)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, (S)-1-methyl-5-phenyl-6-((1-phenylethyl)thio)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 1-methyl-5-phenyl-6-(1-phenylethoxy)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((3-fluorobenzyl)thio)-2-((3-methyloxetan-3-yl)methyl)-5-phenyl-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 3-((6-((3-fluorobenzyl)thio)-4-oxo-5-phenyl-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl)azetidin-1-ium sulfate, 1-methyl-5-phenyl-6-((1-phenylpropyl)thio)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((1-(3-fluorophenyl)ethyl)thio)-1-methyl-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-(cyclohexylthio)-1-methyl-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 1-(oxetan-3-yl)-5-phenyl-6-((1-phenylethyl)thio)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 2-(oxetan-3-yl)-5-phenyl-6-((1-phenylethyl)thio)-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 1-methyl-6-((2-oxocyclopentyl)thio)-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 1-methyl-6-((2-oxocyclohexyl)thio)-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 1-methyl-5-phenyl-6-((2-phenylpropan-2-yl)thio)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 6-((1-(3-hydroxyphenyl)ethyl)thio)-1-methyl-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, 1-methyl-5-phenyl-6-((1-(pyridin-2-yl)ethyl)thio)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, and 1-methyl-5-phenyl-6-((1-(pyridin-3-yl)ethyl)thio)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one:
has a structure selected from:
or a pharmaceutically acceptable salt thereof; or
has a structure
or a pharmaceutically acceptable salt thereof.

### Claim 32

(canceled)

### Claim 33 (depends on 17)

The method of claim 17, wherein the ALDHi is selected from 673A, 257913 (913), 258085 (085), 262548 (548), 263052 (052), 263117 (117), 263118 (118), 263119 (119), 259122 (122), 263646 (646), 264202 (202), or a pharmaceutically acceptable salt thereof.

### Claim 34 (depends on 17)

The method of claim 17, wherein the ALDHi is 673A, or a pharmaceutically acceptable salt thereof.

### Claim 35 (depends on 17)

The method of claim 17, wherein the ALDHi has the structure:
wherein R1 and R2 are independently or together, H, an alkyl, a cycloalkyl, together form a cycloalkyl or heterocyclic alkyl or aryl, an aryl, an alkenyl, a cycloalkyl, alkynl, or a substituted version of the aforementioned groups and R3-R6 are independently a halogen, H, an alkyl, a cycloalkyl, an aryl, an alkenyl, a cycloalkyl, alkynl, or a substituted version of the aforementioned groups, or a pharmaceutically acceptable salt thereof.

### Claim at position 22

36-38. (canceled)

### Claim 39 (depends on 17)

The method of claim 17, for treating cancer in a patient, comprising:
obtaining an antigen-presenting cell or a precursor thereof from the patient, wherein when an antigen-presenting cell precursor is obtained from the patient, further comprising culturing the precursor ex vivo in differentiation medium to differentiate the precursor to an antigen-presenting cell;
culturing the antigen-presenting cell in the presence of an antigen of a cancer cell from the patient to produce a matured antigen-presenting cell; and
administering the matured antigen-presenting cell to the patient with the ALDHi as an adjuvant therapy.

### Claim 40 (depends on 39)

The method of claim 39, wherein the antigen-presenting cell or a precursor thereof is a dendritic cell or a precursor thereof, or a bone marrow progenitor cell, optionally obtained from the patient, and the method comprises differentiating the bone marrow progenitor cell to a dendritic cell.

### Claim at position 25

41-42. (canceled)

### Claim 43 (depends on 17)

The method of claim 17, wherein the ALDHi is administered to the patient on the same day as each instance of the immunotherapy (DO), and optionally for from one to ten days (D1-D10) after the immunotherapy.

### Claim 44

(canceled)

### Claim 45 (depends on 17)

The method of claim 17, wherein the patient has a tumor, and the ALDHi is administered in an amount effective to reduce tumor volume after 100 days in a patient, as compared to a tumor in a patient that is not treated with the ALDHi.

### Claim at position 29

46-47. (canceled)
